^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
New
Source:
Title:

An open-label, multicenter, phase I study of ABBV-399 (telisotuzumab vedotin, teliso-V) as monotherapy (T) and in combination with erlotinib (T+E) in non-small cell lung cancer (NSCLC)

Excerpt:
...50 pts received ≥1 dose of T; 8 of 23 (35%) pts on T+E were EGFR M+ and c-MET+. Rate of c-MET+ among screened NSCLC pts with adenocarcinoma and squamous (Sq) histologies was 64% and 42%, respectively….Safety profiles between T treatment schedules were comparable...Promising activity was seen for T+E in EGFR M+ and c-MET+ NSCLC...
DOI:
10.1093/annonc/mdy292.006
Trial ID: